Last reviewed · How we verify
Lipodystrophy due to Human immunodeficiency virus infection and antiretroviral therapy
Approved treatments
- Egrifta · Theratechnologies
Egrifta works by mimicking the action of growth hormone-releasing hormone to stimulate the release of growth hormone.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Lipodystrophy due to Human immunodeficiency virus infection and antiretroviral therapy patent landscape — cliff calendar, originator estates, attackable patents
- Lipodystrophy due to Human immunodeficiency virus infection and antiretroviral therapy treatment landscape brief
- Lipodystrophy due to Human immunodeficiency virus infection and antiretroviral therapy treatment updates RSS
Frequently asked questions about Lipodystrophy due to Human immunodeficiency virus infection and antiretroviral therapy
What drugs treat Lipodystrophy due to Human immunodeficiency virus infection and antiretroviral therapy?
Tracked treatments include Egrifta.
What is the treatment for Lipodystrophy due to Human immunodeficiency virus infection and antiretroviral therapy?
Standard treatment for Lipodystrophy due to Human immunodeficiency virus infection and antiretroviral therapy includes Egrifta. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Lipodystrophy due to Human immunodeficiency virus infection and antiretroviral therapy patent cliff · Lipodystrophy due to Human immunodeficiency virus infection and antiretroviral therapy CI report
- Treatment: Egrifta · Theratechnologies
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing